Data spanning the past 90 days through January 10, 2026 reveals that Rapport Therapeutics's three principal insider shareholders consist of TenPercentOwner Rock Ventures V, L.P. Third (8.10Mn shares), TenPercentOwner Venture Partners Xii, Llc Arch (3.73Mn shares), Chief Executive Officer Abraham Ceesay (598.81K shares).
| Holder | Position | Shares | Report Date |
|---|---|---|---|
| Rock Ventures V, L.P. Third | 8,104,451 | 10 Jun, 2024 | |
| Venture Partners Xii, Llc Arch | 3,728,738 | 10 Jun, 2024 | |
| Abraham Ceesay | Chief Executive Officer | 598,808 | 18 Dec, 2025 |
| David Bredt | Chief Scientific Officer | 404,075 | 05 Jan, 2026 |
| Krishnaswamy Yeleswaram | Chief Development Officer | 296,991 | 05 Jan, 2026 |
| Cheryl Gault | Chief Operating Officer | 171,928 | 01 Dec, 2025 |
| Steven M Paul | 41,666 | 15 Sep, 2025 | |
| James Healy | 40,851 | 03 Jul, 2024 | |
| Reid M Huber | 20,400 | 15 Sep, 2025 | |
| Troy A. Ignelzi | Chief Financial Officer | 10,000 | 13 Mar, 2025 |
| Wendy B. Young | 9,500 | 11 Sep, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 31 Dec, 2025 | David Bredt | Common Stock | D | 18,000 | - | 410,642 | D | A |
| 31 Dec, 2025 | David Bredt | Common Stock | D | 6,567 | $30.05 | 404,075 | D | S |
| 31 Dec, 2025 | Krishnaswamy Yeleswaram | Common Stock | A | 9,000 | - | 299,831 | D | A |
| 31 Dec, 2025 | Krishnaswamy Yeleswaram | Common Stock | D | 2,840 | $30.05 | 296,991 | D | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 600 | $31.04 | 567,913 | D | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 2,441 | $28.84 | 571,305 | D | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 515 | $31.04 | 30,895 | I | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 2,792 | $30.04 | 568,513 | D | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 2,147 | $28.84 | 33,831 | I | S |
| 17 Dec, 2025 | Abraham Ceesay | Common Stock | D | 2,421 | $30.04 | 31,410 | I | S |
| 15 Dec, 2025 | David Bredt | Common Stock | D | 7,704 | $29.95 | 393,438 | D | S |
| 15 Dec, 2025 | David Bredt | Common Stock | D | 796 | $30.68 | 392,642 | D | S |
| 26 Nov, 2025 | Cheryl Gault | Common Stock | A | 5,000 | $1.80 | 176,928 | D | M |
| 26 Nov, 2025 | Cheryl Gault | Common Stock | D | 5,000 | $30.10 | 171,928 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,242 | $24.91 | 38,819 | I | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 3,056 | $25.43 | 573,746 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,777 | $24.92 | 576,802 | D | S |
| 17 Nov, 2025 | Abraham Ceesay | Common Stock | D | 2,841 | $25.44 | 35,978 | I | S |
| 17 Nov, 2025 | David Bredt | Common Stock | D | 5,344 | $25.39 | 401,142 | D | S |
| 17 Nov, 2025 | David Bredt | Common Stock | D | 3,156 | $24.84 | 406,486 | D | S |